binx health

The presentation will be webcast live and may be accessed by visiting https://wsw.com/webcast/canaccord37/binx/. ABOUT BINX HEALTH binx health is the pioneer in anywhere care in women’s health for consumers where they live, work and shop. With the first FDA 510(k) cleared solution for the rapid testing of Chlamydia (CT) and Gonorrhea (NG) in women, binx is poised to transform care for the two most tested for sexually-transmitted infections globally. Today, 40% of patients who test positive for CT/NG do not come back for treatment once they leave a physician’s office—making the need for rapid test and treat solutions paramount. ’s investors include financial investors Johnson & Johnson Innovation, Novartis Venture Fund, LSP, BB Biotech, RMI Investments and Technology Venture Partners and strategic investors Consort Medical (whose wholly owned subsidiary

binx FDA-cleared platform already impacting human health—poised to transform care for millions. ’s health, today announced the first real-world use of the binx io platform, delivering same-visit diagnosis and treatment for chlamydia (CT) and gonorrhea (NG)—the two most tested-for sexually transmitted infections (STIs) globally. The World Health Organization (WHO) has previously indicated that the lack of reliable, low-cost, point-of-care tests that enable diagnosis and treatment in a single visit represents a major barrier to sexually transmitted infection (STI) control and prevention. With the company’s recent CE Mark in Europe and FDA 510(k) clearance for rapid CT/NG testing, binx health is the first company to remove this barrier.

It’s reasonable to assume that all sexually transmitted infections (STIs) – a.k.a. sexually transmitted diseases (STDs) – are transmitted through sexual contact. Although kissing is a low risk sexual activity, it is still possible to pass herpes, HPV, and rarely syphilis, through kissing. While STI transmission via oral sex is quite possible, studies have shown that the risk of getting HIV from oral sex is much lower than the risk associated with vaginal sex. Use barrier methods such as condoms and oral dams the right way every time you have oral sex to lower your chances of transmitting or acquiring an infection.

’s health, today announced the first real-world use of the binx io platform, delivering same-visit diagnosis and treatment for chlamydia (CT) and gonorrhea (NG)—the two most tested-for sexually transmitted infections (STIs) globally. The binx health io CT/NG Assay, when tested using the binx health io Instrument, is a fully automated, qualitative test intended for use in point-of-care or clinical laboratory settings for the rapid detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in female vaginal swab specimens collected either by a clinician or self-collected by a patient in a clinical setting. We do this through the development of (1) proprietary, rapid desktop PCR instruments for retail pharmacy, urgent care, primary care, health centers, and any other brick-and-mortar location where onsite, on-demand testing and rapid results on par with central lab testing, are paramount, and (2) mobile solutions for at-home, physician-ordered testing that aim to bring consumers from “worry-to-well” in the palm of their hands. St George’s, University of London (informally St George’s or SGUL, formerly St George’s Hospital Medical School) is a medical school located in London, United Kingdom and a constituent college of the University of London.